Rosuvastatin ( DrugBank: Rosuvastatin )


11 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
18脊髄小脳変性症(多系統萎縮症を除く。)1
46悪性関節リウマチ6
49全身性エリテマトーデス5
51全身性強皮症1
56ベーチェット病1
79家族性高コレステロール血症(ホモ接合体)11
96クローン病2
97潰瘍性大腸炎2
271強直性脊椎炎1
299嚢胞性線維症1

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03970798
(ClinicalTrials.gov)
May 22, 201923/5/2019A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinA Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or RosuvastatinParkinson's DiseaseDrug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356Kyowa Kirin Co., Ltd.NULLCompleted20 Years44 YearsMale50Phase 1Japan

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02705547
(ClinicalTrials.gov)
May 20165/3/2016Rosuvastatin (Crestor) in Friedreich AtaxiaOpen-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich AtaxiaFriedreich AtaxiaDrug: RosuvastatinChildren's Hospital of PhiladelphiaFriedreich's Ataxia Research AllianceCompleted18 Years65 YearsAll12Early Phase 1United States

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04608344
(ClinicalTrials.gov)
November 4, 202023/10/2020Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsA Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsRheumatoid ArthritisDrug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: FilgotinibGilead SciencesGalapagos NVCompleted18 Years55 YearsAll27Phase 1United States
2NCT01389388
(ClinicalTrials.gov)
January 201316/4/2010Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint DiseaseCholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint DiseasesCarotid Artery Plaque;Ankylosing Spondylitis;Rheumatoid ArthritisDrug: RosuvastatinDiakonhjemmet HospitalNULLCompleted35 Years80 YearsBoth114N/ANorway
3NCT01725230
(ClinicalTrials.gov)
November 20127/11/2012Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With FostamatinibAn Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice DailyRheumatoid ArthritisDrug: Fostamatinib;Drug: Rosuvastatin;Drug: SimvastatinAstraZenecaNULLCompleted18 Years55 YearsBoth42Phase 1United States
4NCT00555230
(ClinicalTrials.gov)
July 20077/11/2007Effects of HMG-coA Reductase Inhibitor on Rheumatoid ArthritisEffects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid ArthritisRheumatoid ArthritisDrug: Rosuvastatin;Drug: PlaceboChinese University of Hong KongNULLCompleted18 Years75 YearsBoth150Phase 2China
5EUCTR2004-001909-10-GB
(EUCTR)
02/02/200515/08/2005Effect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis - RORA trialEffect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis - RORA trial Rheumatoid ArthritisTrade Name: rosuvastatin
Product Name: rosuvastatin
Product Code: ZD 4522
University of DundeeNULLNot RecruitingFemale: yes
Male: yes
United Kingdom
6NCT00679510
(ClinicalTrials.gov)
February 200415/5/2008Rosuvastatin in Rheumatoid Arthritis (RORA)Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: rosuvastatin;Drug: placeboUniversity of DundeeNULLCompleted40 YearsN/AAll50Phase 2/Phase 3United Kingdom

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 733 - (DrugBank : 186) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 198
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01953835
(ClinicalTrials.gov)
October 4, 201326/9/2013A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184A Two-part Healthy Volunteer Study to Investigate Both the Interaction of GSK2586184 With Rosuvastatin and Simvastatin and to Compare the Pharmacokinetics of Two Different Formulations of GSK2586184Systemic Lupus ErythematosusDrug: GSK2586184 standard formulation;Drug: Simvastatin;Drug: Rosuvastatin;Drug: GSK2586184 new formulationGlaxoSmithKlineNULLCompleted18 Years65 YearsAll37Phase 1United States
2NCT01170585
(ClinicalTrials.gov)
July 201026/7/2010A Trial of Rosuvastatin in Systemic Lupus ErythematosusA Randomised Placebo Controlled Trial of Rosuvastatin in Systemic Lupus ErythematosusAtherosclerosis;Systemic Lupus ErythematosusDrug: Rosuvastatin;Drug: PlaceboImperial College LondonNULLCompleted18 Years80 YearsBoth33Phase 2United Kingdom
3EUCTR2006-006214-16-GB
(EUCTR)
23/02/201029/02/2008A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus. - RCT of statin in SLEA randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus. - RCT of statin in SLE Systemic lupus erythematosus.
MedDRA version: 13.1;Level: LLT;Classification code 10042944;Term: Systemic lupus erythematosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Trade Name: Crestor
Product Name: Crestor
INN or Proposed INN: ROSUVASTATIN CALCIUM
Other descriptive name: rosuvastatin
Trade Name: Crestor
Product Name: Crestor
INN or Proposed INN: ROSUVASTATIN CALCIUM
Other descriptive name: rosuvastatin
Imperial CollegeNULLNot Recruiting Female: yes
Male: yes
64 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
4NCT00866229
(ClinicalTrials.gov)
April 200819/3/2009Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol LevelEfficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol LevelSystemic Lupus Erythematosus;High LDL Cholesterol LevelDrug: Rosuvastatin;Drug: SimvastatinRamathibodi HospitalAstraZenecaRecruiting18 Years60 YearsBoth140Phase 4Thailand
5NCT00371501
(ClinicalTrials.gov)
June 20061/9/2006Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus ErythematosusLow Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled TrialAtherosclerosis;Thromboembolism;Systemic Lupus ErythematosusDrug: Rosuvastatin;Drug: placebo;Drug: aspirinTuen Mun HospitalAstraZenecaCompleted18 YearsN/ABoth72Phase 4Hong Kong

51. 全身性強皮症


臨床試験数 : 523 薬物数 : 617 - (DrugBank : 156) / 標的遺伝子数 : 113 - 標的パスウェイ数 : 214
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00984932
(ClinicalTrials.gov)
September 200824/9/2009Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary HypertensionThe Effect of Rosuvastatin on Vascular Dysfunction and Inflammatory Markers in Systemic Sclerosis-related Pulmonary Hypertension: Randomized, Double-Blind Placebo-Controlled TrialSystemic SclerosisDrug: RosuvastatinFaculty of Medicine, University of AlexandriaNULLCompletedN/AN/ABoth40Phase 3Egypt

56. ベーチェット病


臨床試験数 : 76 薬物数 : 111 - (DrugBank : 32) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04328064
(ClinicalTrials.gov)
May 201029/8/2011The Role of Rosuvastatin on Vascular Involvement in Behçet's DiseaseBehcet's DiseaseDrug: Rosuvastatin calcium 40mg;Drug: Placebo oral tabletUniversity of AlexandriaNULLCompleted17 Years65 YearsAll56N/ANULL

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 142 薬物数 : 119 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510715
(ClinicalTrials.gov)
August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States
2NCT02434497
(ClinicalTrials.gov)
June 6, 20157/4/2015A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial Hypercholesterolemia (HoFH)Drug: Rosuvastatin 20mgAstraZenecaNULLCompleted6 Years18 YearsAll9Phase 3Belgium;Canada;Denmark;Israel;Malaysia;Taiwan
3EUCTR2014-004746-99-DK
(EUCTR)
27/03/201527/03/2015A study to evluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH).
MedDRA version: 19.0;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Film-Coated Tablet
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: Rosuvastatin calcium
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
20Phase 3United States;Taiwan;Canada;Malaysia;Belgium;Lebanon;Denmark;Israel;Netherlands;Germany;Sweden
4EUCTR2014-004746-99-BE
(EUCTR)
23/02/201518/12/2014A study to evluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH).;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Crestor Film-Coated Tablet
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: Rosuvastatin calcium
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
20Phase 3United States;Taiwan;Canada;Malaysia;Belgium;Lebanon;Denmark;Israel;Netherlands;Germany;Sweden
5EUCTR2014-000972-24-DK
(EUCTR)
17/12/201425/09/2014A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial HypercholesterolemiaA Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) - HYDRA Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 17.0;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
25United States;Taiwan;Canada;Malaysia;Belgium;Lebanon;Denmark;Israel;Germany;Netherlands;Sweden
6EUCTR2014-000972-24-DE
(EUCTR)
17/11/201426/09/2014A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial HypercholesterolemiaA Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) - HYDRA Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 17.1;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
25United States;Taiwan;Hong Kong;Israel;United Kingdom;Czech Republic;Belgium;Denmark;Australia;South Africa;Germany;Netherlands;Norway;Sweden
7NCT02226198
(ClinicalTrials.gov)
November 201414/8/2014A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaA Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial Hypercholesterolemia (HoFH)Drug: Rosuvastatin 20mg;Drug: PlaceboAstraZenecaNULLCompleted6 Years17 YearsAll20Phase 3Belgium;Canada;Denmark;Israel;Malaysia;Netherlands;Taiwan;Germany;Lebanon;Sweden;United States
8EUCTR2014-000972-24-BE
(EUCTR)
27/10/201411/09/2014A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial HypercholesterolemiaA Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) - HYDRA Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 17.1;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
25Phase 3United States;Taiwan;Hong Kong;Israel;United Kingdom;Czech Republic;Belgium;Australia;Denmark;South Africa;Germany;Netherlands;Norway;Sweden
9EUCTR2014-000972-24-NL
(EUCTR)
20/10/201405/08/2014A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial HypercholesterolemiaA Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) - HYDRA Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 17.1;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
25United States;Taiwan;Hong Kong;Israel;United Kingdom;Czech Republic;Belgium;Australia;Denmark;South Africa;Germany;Netherlands;Norway;Sweden
10EUCTR2014-000972-24-SE
(EUCTR)
20/08/201430/06/2014A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial HypercholesterolemiaA Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) - HYDRA Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 17.1;Level: LLT;Classification code 10054380;Term: Familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Crestor Tablets (calcium rosuvastatin) Film-Coated tablets
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: calcium rosuvastatin
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
25United States;Taiwan;Hong Kong;Israel;United Kingdom;Czech Republic;Belgium;Australia;Denmark;South Africa;Germany;Netherlands;Norway;Sweden
11EUCTR2014-004746-99-SE
(EUCTR)
23/12/2014A study to evluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH).;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Crestor Film-Coated Tablet
Product Name: Crestor
Product Code: ZD4522
INN or Proposed INN: Rosuvastatin calcium
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
20Phase 3United States;Taiwan;Canada;Malaysia;Belgium;Lebanon;Denmark;Israel;Netherlands;Germany;Sweden

96. クローン病


臨床試験数 : 2,400 薬物数 : 1,417 - (DrugBank : 267) / 標的遺伝子数 : 168 - 標的パスウェイ数 : 214
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01489943
(ClinicalTrials.gov)
September 19, 20111/12/2011A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsA Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsCrohn's DiseaseDrug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mgGlaxoSmithKlineNULLCompleted18 Years55 YearsAll24Phase 1United States
2JPRN-UMIN000002074
2009/07/0101/07/2009Rosuvastatin for Acute Systemic Crohn's disease: A mono-center randomized triaL Crohn's diseaseRosuvastatin (Crestor) 0mg/day: Control group
Rosuvastatin (Crestor) 5mg/day: Low-dose group
Rosuvastatin (Crestor) 20mg/day: High-dose group
Department of lower gastroenterology, Hyogo College of MedicineNULLComplete: follow-up complete20years-old65years-oldMale and Female45Phase 2Japan

97. 潰瘍性大腸炎


臨床試験数 : 2,527 薬物数 : 1,503 - (DrugBank : 259) / 標的遺伝子数 : 143 - 標的パスウェイ数 : 201
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04883840
(ClinicalTrials.gov)
October 22, 20206/5/2021Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative ColitisDrug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative ColitisUlcerative ColitisDrug: Rosuvastatin 10mgUniversitaire Ziekenhuizen LeuvenVlaams Instituut Biotechnologie (VIB)Recruiting18 Years70 YearsAll220Phase 2/Phase 3Belgium
2EUCTR2019-004208-37-BE
(EUCTR)
03/08/202004/03/2020Statins for treating ulcerative colitis through GI microbiomeDrug repurposing - Statins as microbiota modulating agents in ulcerative colitis - ReMiDy There are two population groups, 20 healthy volunteers and at least 150 individuals diagnosed with mild/moderate active ulcerative colitis or are in remission.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Rosuvastatine EG
Product Name: rosuvastatin
INN or Proposed INN: rosuvastatin
Other descriptive name: ROSUVASTATIN CALCIUM
UZ LeuvenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 3Belgium

271. 強直性脊椎炎


臨床試験数 : 563 薬物数 : 374 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01389388
(ClinicalTrials.gov)
January 201316/4/2010Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint DiseaseCholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint DiseasesCarotid Artery Plaque;Ankylosing Spondylitis;Rheumatoid ArthritisDrug: RosuvastatinDiakonhjemmet HospitalNULLCompleted35 Years80 YearsBoth114N/ANorway

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,658 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002387-32-GB
(EUCTR)
05/08/201427/06/2014Trial of Rosuvastatin for the Prevention of Kidney Toxicity caused by Tobramycin in Children with Cystic FibrosisPhase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis - PROteKT Aminoglycoside-induced nephrotoxicity
MedDRA version: 18.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 18.0;Classification code 10069022;Term: Kidney injury molecule-1;System Organ Class: 10022891 - Investigations
MedDRA version: 18.0;Level: LLT;Classification code 10067571;Term: Nephrotoxicity;System Organ Class: 100000004857;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: Crestor
Product Name: Crestor
INN or Proposed INN: Rosuvastatin calcium
University of LiverpoolNULLNot RecruitingFemale: yes
Male: yes
50Phase 2United Kingdom